Journal
ONCOTARGET
Volume 9, Issue 1, Pages 1380-1402Publisher
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.22377
Keywords
drug therapy resistance mechanisms; cancer chemotherapy; cancer-associated glycosylations; glycosyltransferases; colorectal cancer
Categories
Funding
- Ligue Contre le Cancer/Comite du Nord
- Fondation ARC (Association pour la Recherche sur le Cancer)
- Region Nord-Pas de Calais (Cancer Regional Program)
- University of Lille
- Centre National de la Recherche Scientifique
- Ministere de l'Enseignement Superieur et de la Recherche
Ask authors/readers for more resources
Colorectal cancer (CRC) is the fourth leading cause of cancer-related deaths in the world. Drug resistance of tumour cells remains the main challenge toward curative treatments efficiency. Several epidemiologic studies link emergence and recurrence of this cancer to metabolic disorders. Glycosylation that modifies more than 80% of human proteins is one of the most widepread nutrient-sensitive post-translational modifications. Aberrant glycosylation participates in the development and progression of cancer. Thus, some of these glycan changes like carbohydrate antigen CA 19-9 (sialyl Lewis a, sLea) or those found on carcinoembryonic antigen (CEA) are already used as clinical biomarkers to detect and monitor CRC. The current review highlights emerging evidences accumulated mainly during the last decade that establish the role played by altered glycosylations in CRC drug resistance mechanisms that induce resistance to apoptosis and activation of signaling pathways, alter drug absorption and metabolism, and led to stemness acquisition. Knowledge in this field of investigation could aid to the development of better therapeutic approaches with new predictive biomarkers and targets tied in with adapted diet.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available